BioAtla (BCAB) Earnings Analysis

BioAtla (BCAB) next reports earnings on 2026-08-06, consensus EPS -8.5 USD. Last quarter (2026-05-15) it beat with EPS -6.18 USD vs -10 USD est (+38.2%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -0.08.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BCAB next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-8.5 USD
Revenue estimaten/a

BCAB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-6.18 USD-10 USD+38.2%Beat
2026-03-31-8 USD-12 USD+33.3%Beat
2025-11-13-0.27 USD-0.31 USD+12.9%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

BCAB valuation and analyst view

Trailing P/E-0.08
Trailing EPS-33.70761 USD
Price / book-0.14
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (6 buy / 3 hold / 0 sell)

Related research pages

Frequently asked questions

When is BioAtla (BCAB)'s next earnings date?

BioAtla is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -8.5 USD.

Did BCAB beat earnings last quarter?

In its 2026-05-15 report, BCAB posted EPS of -6.18 USD versus a -10 USD estimate — a beat of 38.2%.

What is BCAB's earnings track record?

Over the last 3 reported quarters with consensus data, BCAB beat estimates 3 times (100%).

What is BCAB's current P/E ratio and EPS?

BCAB trades at a trailing P/E of -0.08 on trailing EPS of -33.70761076656396 USD.

What do analysts rate BCAB?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell).